ARRY - I gather that one reason for the positive reaction could be that the PR states that there could be a P3 for selumetinib completed by 2013. That's intriguing if I understood it correctly. Sounds like a small trial powered for PFS if true. Do you recall this being addressed during the CC?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.